Six Pharma CEOs To Testify In House as Democrats, Trump Compete For Attention On Drug Pricing

While neither party is likely to make any big policy changes this year, the action from both sides of the aisle indicates politicians still see going after pharma as a winning issue with voters even as polls show voters are focused elsewhere. 

Medical business or prices concept. Making money in pharmaceutical industry or high medical expenses. Also drug dealing, dealer or trade. Dollar sign written with pills spilled from a medicine bottle.
Six pharma CEOs will testify at the House of Representatives on drug pricing next week • Source: Shutterstock

Democrats moved to take back control of the drug pricing conversation in the US this week, announcing a two-day House Oversight and Reform Committee hearing that will feature six pharmaceutical CEOs targeted for the high prices of a half dozen drugs. The 22 September hearing announcement follows a string of drug pricing executive orders by President Donald Trump.

The 30 September hearing will feature former Celgene Corporation CEO Mark Alles and Bristol-Myers Squibb Company CEO Giovanni Caforio to discuss cancer drug Revlimid. Teva Pharmaceutical Industries...

More from Pricing Debate

More from Market Access